An enzyme-linked immunosorbent assay (ELISA) was evaluated for serum alpha-fetoprotein determination in the antenatal screening for fetal open neural tube defects. The ELISA was used concurrently with an existing radioimmunoassay (RIA) method until serum specimens from 5000 pregnant women, between 15 and 20 weeks gestation, had been tested. The accuracy of the ELISA was similar to that of the RIA; the median AFP values by gestational week obtained with the ELISA were, on average, 2 KIU/L higher than the corresponding RIA values; the 10 th and 90 t h percentiles. in terms of multiples of the median (MoM), were very similar. The precision of the two methods was also similar. The ELISA method yielded 1·8% results from unaffected pregnancies above 2·5 MoM compared with 1·4% by RIA, a small but statistically significant difference (P=0·03). Both methods detected the same affected pregnancies identified during this period; five open neural tube defects, three with exomphalos and three intra-uterine deaths. The ELISA method was simple, required about one quarter less operator time than the RIA and enabled results to be generated in one day rather than the two days required by RIA. The ELISA method is a suitable alternative to RIA for routine use in screening for fetal neural tube defects.
SUMMARY.
An enzyme-linked immunosorbent assay (ELISA) was evaluated for serum alpha-fetoprotein determination in the antenatal screening for fetal open neural tube defects. The ELISA was used concurrently with an existing radioimmunoassay (RIA) method until serum specimens from 5000 pregnant women, between 15 and 20 weeks gestation, had been tested. The accuracy of the ELISA was similar to that of the RIA; the median AFP values by gestational week obtained with the ELISA were, on average, 2 KIU/L higher than the corresponding RIA values; the 10 th and 90 t h percentiles. in terms of multiples of the median (MoM), were very similar. The precision of the two methods was also similar. The ELISA method yielded 1·8% results from unaffected pregnancies above 2·5 MoM compared with 1·4% by RIA, a small but statistically significant difference (P=0·03). Both methods detected the same affected pregnancies identified during this period; five open neural tube defects, three with exomphalos and three intra-uterine deaths. The ELISA method was simple, required about one quarter less operator time than the RIA and enabled results to be generated in one day rather than the two days required by RIA. The ELISA method is a suitable alternative to RIA for routine use in screening for fetal neural tube defects.
Antenatal screening for fetal open neural tube defects (NTDs), using maternal serum alphafetoprotein (AFP) estimation, is usually based on radioimmunoassal. (RIA) techniques. These assays employ the 12 Iodine isotope label which has a short shelf-life of about 2 months. Of the various alternatives to RIA, the enzyme-linked immunosorbent assay (EL.ISA) offers several promising advantages. The method uses an enzyme label, which has a long shelf-life (in excess of one year), rather than an isotope label, and the method is amenable to simple automation. It is the purpose of this report to describe the evaluation of an ELISA method for routine use in screening for fetal open NTD's.
Materials and methods

Serum specimens collected from all women
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undergoing AFP screening at the John Radcliffe Hospital, Oxford, between June 1982 and June 1983, were divided and tested by RIA (the established method) and ELISA (the new method). Only those specimens tested between 15 and 20 weeks gestation were included in the analyses and the study was continued until there were 5000 singleton pregnancies without a known NTD, exomphalos or intra-uterine death. The gestational age was estimated as the time since the first day of the last menstrual period. During this period serum samples from five pregnancies with a NTD, three with exomphalos, three with intra-uterine death and 15 twin pregnancies were also tested.
ASSAY METHODS
ELISA
The AFP ELISA method was based on the sandwich-enzyme immunoassay procedure and has been previously described.' Two 10 !J.L samples of each serum specimen were applied to adjacent wells of a 96-well microtitre plate pre-coated with rabbit anti-human AFP. After incubating for 2 h at room temperature peroxidase-labelled rabbit anti-AFP was added to each well and incubated for a further 3 h. After a final incubation of 15 min at room temperature with the enzyme substrate orthophenylenediarnine the absorbance of each well was measured at 490 nm using an automated microtitre plate reader linked directly to a microcomputer. Absorbances were converted into AFP concentrations using a least-squares linear and cubic regression (AFP conc.=a + b (absorbancej-r-crabsorbance)." where a, band c are constants).
RIA
This was a single-antibody RIA using rabbit anti-human AFP (Dakopatts) and an 125I_AFP label (the pure AFP was obtained from the Foundation for Blood Research, Scarborough, USA and iodinated in the Physics Department, Royal Berkshire Hospital, Reading, U'K). Serum samples (100~L) were analysed in duplicate with an overnight incubation with antibody and label, followed by the addition of polyethylene glycol and centrifugation to separate bound label from free label. The gamma counts obtained for the bound fraction were converted into AFP concentration using a least squares quadratic logit-Iog regression (logit Y=al +b l (AFP)+cl(AFP),2 where logit Y=log [YI(l-Y)], Y=[counts bound/zero dose counts bound] and at> b, and CI are constants).
Standards
Eight standards, with AFP concentrations ranging from 0-220 KIU/L, were obtained by preparing known dilutions of the British Human Cord Serum Standard (721227) in a pool of human plasma with an AFP concentration of less than 1 KIU/L. Aliquots of these standards were stored at -40°C and used in both the ELISA and RIA methods.
Quality assessment samples
Two sets of three quality assessment (QA) pools of maternal serum were used to estimate within and between-batch assay variance. One existing set, prepared with AFP concentrations of about 1·0, 2·5 and 5·0 multiples of the median value (MoM) at 17 weeks' gestation for pregnancies without NTDs was used for the RIA, and a new set was prepared for ELISA since we did not wish to consume the stocks of Alpha-fetoprotein ELISA 335 the existing set used for the RIA. Samples from each pool were stored at -40°C and analysed, in duplicate, at the beginning and end of each analytical batch.
ASSAY EVALUATION METHODS
The ELISA and RIA methods were evaluated: (i) using the performance measures recommended by an international working group which met in Washington in 1978 (Washington Group Reporr'): (ii) by estimating three components of assay imprecision, and (iii) with respect to criteria for short term epidemiological monitoring previously described."
Washington Group Report performance measures Relative assay accuracy. A serum sample with an AFP concentration of about 5·() MoM, at 17 week's gestation, was accurately diluted, using serum of negligible AFP concentration, to yield samples with AFP concentrations of exactly 1/10, 1/5, 2/5, 3/5 and 4/5 of the original concentration, i.e. about 0·5, 1·0,2·0,3·0 and 4·0 MoM respectively. Each prepared dilution, as well as the original sample, was then assayed six times in one analytical batch and the geometric mean calculated. The expected AFP concentration of each dilution was calculated by defining the value for the 1·0 MoM sample as the expected value for that dilution. The ratio of observed to expected AFP concentrations, for each dilution, were then estimates of relative accuracy.
Absolute assay imprecision (across-batch imprecision). This was estimated by selecting, at random, one of the four 2·5 MoM QA Pool replicates in each analytical batch and calculating the standard deviation (SO) of 10glO AFP across all the batches.
Relative assay imprecision. This was estimated by dividing the above S02 by the variance of 10glO[AFP] among the 1436 singleton pregnancies without NTO, exomphalos or intra-uterine death, studied at 17 weeks gestation.
Components of assay imprecision
The results from the QA pools were used to estimate the within-batch, and between-batch, and total assay variance at different levels of AFP. One-way analysis of variance of loglll' [AFP] by batch (221 batches for ELISA and 88 for RIA) was used, and the estimation of variance components followed standard methods." Since QA samples were included at both the beginning and end of each batch we were able to determine whether the withinbatch variance contained a component due to systematic assay drift. This analysis of variance was performed for two reasons: (i) to determine whether the stability of ELISA reagents resulted in a smaller between-batch variance than RIA, and (ii) to determine whether assay drift was an important component of within-batch variance.
Short-term epidemiological monitoring
The median, 10 th and 90 th percentile serum AFP results for the 5000 women who had singleton pregnancies without NTD, exomphalos or an intra-uterine death were calculated for each week of pregnancy. Regressed median values (obtained by log-linear regression) were used to convert the individual AFP results from all 5026 women studied into MoM for their respective completed gestational week. The numbers equal to or greater than 2·5 MoM were tabulated according to pregnancy outcome.
Results
WASHINGTON GROUP REPORT
PERFORMANCE MEASURES
A comparison of the ELISA and RIA with the recommended performance measures is shown in Table 1 . Both assays were less accurate at values around 0·5 MoM but only one result was outside the recommended limits of 0·9-1·1; this was the ELISA value of 0·84 for the 0·5 MoM dilution. The across-batch assay imprecision was 0·0366 loglll[AFP] in international units (CV=8'4%) for ELISA and 0·0437 10glll[AFPj(CV=1O·0%) for RIA, both very similar and well within the recommended limit of 0·12 10glll[AFPj in international units (CV=28%). The relative assay imprecision was 3·7% for ELISA and 4·7% for RIA, well within the recommended limit of 25%.
COMPONENTS OF ASSAY IMPRECISION
The calculated components of assay imprecision for both the ELISA and RIA are given in Table 2 for each of the QA pools. The within-batch, between-batch and total assay variances were similar for both methods, the between-batch component being generally smaller than the within-batch component.
There was evidence of systematic downwards drift in the ELISA method which increased with AFP concentration. On average the 1 MoM, 2·5 MoM and 5 MoM QA pools were 2%, 4% and 8% lower at the end of each ELISA batch and it was estimated that this assay drift accounted for 2%, 11% and 31% of the within-batch variance at each respective AFP concentration. There was no evidence of systematic drift in the RIA method. Table 3 compares the median, 10 th and 90 th The outcome of pregnancies with serum AFP results equal to or greater than 2·5 MoM by both ELISA and RIA are given in Table 4 . The five pregnancies associated with an open NTD, the three with exomphalos and the three with intra-uterine death yielded positive AFP results by both methods. ELISA yielded positive results from 92 pregnancies not associated with a NTD, exomphalos or intra-uterine death whilst RIA yielded 72. This difference was statistically significant using the McNemar test (P=0·03). The fifteen twin pregnancies had positive results by RIA and 14 of these were positive by ELISA.
Short-term epidemiological monitoring
Discussion
Serum AFP assays used for the antenatal screening of fetal NTDs need to provide consistent results over long periods since even a small change in performance can alter the detection rate and/or the false positive rate. The ELISA method was assessed specifically for routine use in the antenatal detection of fetal NTDs and satisfied the performance measures recommended by the Washington Group Report, with the exception of the relative accuracy result on the 0·5 MoM dilution (Table 1) . This probably reflects a difference in assay sensitivity since the ELISA assay is recommended for use with samples containing more than 20 KIU/L (although the assay conditions can be modified to provide greater sensitivity), whereas the RIA method used here can measure 10 KIU/L adequately. Nonetheless, this did not appear to be important since in all other respects the ELISA and RIA performance was similar.
The precision of ELISA and RIA was similar at the three levels of AFP concentration studied ( Table 2 ). However, the ELISA was subject to some assay drift. This is probably due to the time dependence of the final incubation stage of the assay and might be reduced by adopting careful, timed addition of reagents.
From the point of view of screening, the ELISA identified the same affected pregnancies as RIA (Table 4) but also yielded a few more false-positive AFP results, i.e. 92 results above 2·5 MoM from singleton pregnancies not associated with a NTD, exomphalos or intrauterine death by ELISA compared to 72 by RIA (Table 3 ). This would be likely to increase slightly the aminiocentesis rate among unaffected women. However, this small difference would not make the ELISA unsuitable for screening purposes. It seems unlikely that further investigation into the possible cause of the excess of false positive results (4/1000), even if the factors responsible were identified, would alter the conclusion, Table 5 provides a comparison of operator time involved in performing serum AFP tests on 100 patient samples by both ELISA and RIA. The ELISA method required about one quarter less operator time than RIA and by using an automated pipette and plate reader on line to a microcomputer we were able to generate results in one day rather than the 2 days currently required by the RIA. We also found the ELISA method easy to learn and use.
We conclude that the ELISA method, although offering no clear advantage over RIA, is a suitable alternative to RIA for routine use in the determination of serum AFP in screening for NTDs.
